Highlights in myasthenia gravis from AANEM 2024 include efficacy data on efgartigimod, ravulizumab, zilucoplan, and first-in-class inebilizumab, as well as safety outcomes in pregnancy for eculizumab.

Increased demands from an aging population and pandemic-related supply shortages leave provinces scrambling to allocate ...

First, there were “Ozempic babies.” Now, there is also Ozempic-before-baby. Unplanned pregnancies are still regularly being ...

The US Food and Drug Administration (FDA) sometimes allows cancer drugs with accelerated approvals to remain on the market ...

The first pregnancy guideline updates from the American Thyroid Association since 2017 to emphasize shared decision-making, ...

Individuals at an increased risk of developing rheumatoid arthritis (RA) have a unique gut microbial composition, ...

Higher plasma levels of omega-6 and omega-3 fatty acids are associated with a lower incidence of cancer. However, omega-3 ...

The use of semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), is not associated with an increased risk for ...

In September this year in Rome, an older woman died, and her daughter spent a week in intensive care after eating a few ...

SAN ANTONIO — Several types of anti-obesity medications (AOMs), including glucagon-like peptide 1s (GLP-1s), are associated ...

PHILADELPHIA — Patients with celiac disease who take an angiotensin receptor blocker (ARB) may experience worse outcomes, ...

Nearly a quarter of patients with hidradenitis suppurativa (HS) experienced concomitant eye disease, and among those who did, ...